Hemodialysis in Patients Requiring ¹³¹I Treatment for Thyroid Carcinoma

Abstract

We conclude that a successful reduction of radioactivity, without dispersing its therapeutic efficacy, can be obtained with daily hemodialysis with a CRRT machine in patients in isolation treated with 131I. A therapeutic model is proposed.

HOTAIR is a promising novel biomarker in patients with thyroid cancer

“…Thyroid carcinoma (TC) is the most common endocrine malignancy accounting for >90% of endocrine gland malignancies (1). Effective treatment in the majority of patients with TC includes total thyroidectomy followed by therapy with radioactive iodide (2).…”

Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

“…After a full-text screening we excluded another 31 studies for various reasons: they gave no relevant information on dosing or aspects related to dosing ( n = 18), they addressed only the radiation safety of staff ( n = 5), described renal imaging ( n = 5), or were review ( n = 3). A total of 34 studies remained for inclusion in this systematic review (Akers et al 2016 ; Aktaş et al 2008 ; Alevizaki et al 2006 ; Bhat et al 2017 ; Courbon et al 1997 , 2006 ; Culpepper et al 1992 ; Daumerie et al 1996 ; Demko et al 1998 ; Driedger et al 2006 ; El-Zeftawy et al 2017 ; Fofi et al 2013 ; Holst et al 2005 ; Howard and Glasser 1981 ; Jiménez et al 2001 ; Kaptein et al 2000 ; Kode et al 2017 ; Laffon et al 2008 ; Magné et al 2002 ; McKay and Malaroda 2019 ; McKillop et al 1985 ; Mello et al 1994 ; Minamimoto et al 2007 ; Miyasaka et al 1997 ; Morrish et al 1990 ; Pahlka and Sonnad 2006 ; Sinsakul and Ali 2004 ; Tobes et al 1989 ; Toriihara et al 2015 ; Toubert et al 2001 ; Vermandel et al 2020 ; Wang et al 2003 ; Willegaignon et al 2010 ; Yeyin et al 2016 ). The selection process is illustrated in a PRISMA flow diagram (Fig.…”

“…One study reduced the dose to 75% of the standard dose in two patients, based on literature also included in our review, and started HD 24 h after administration of the dose, followed by daily HD until a safe radiation dose rate was reached (Fofi et al 2013 ). Another study recommended a 30% reduction in dose for ablative or adjuvant therapies and a dose based on pretherapeutic dosimetry studies for metastatic patients.…”

Can radioiodine be administered effectively and safely to a patient with severe chronic kidney disease?

“…The lack of thyroid tissue to take up and store the iodine also affects the clearance of I‐311. The size of the administered dose of I‐131, the dialysis dose, the time between the administration of I‐131 and the performance of the dialysis and the time between dialyses in patients with ESRD have given rise to substantial controversy . According to one proposed protocol, I‐131 should be administered 48–72 h after the last dialysis at a dose that constitutes 25% of the calculated total dose, and the next dialysis should be performed 24 h after the administration of the radioisotope .…”

“…Literature evaluating efficacy and safety of radioiodine therapy for thyroid cancer in patients with end-stage renal disease13,[15][16][17][20][21][22][23][24][25][26][27]29,37 …”